Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | POLA1 | P09884 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 3/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29351943 | 0.82 | CYP2C19 (0.98) | CYP2C19POLA1LMNAHTTRECQL | |
| Apaxifylline SCHEMBL13275927 | 0.77 | ADORA1 (0.48) | CYP2C19POLA1LMNAHTTRECQL | |
| Aphidicolin SCHEMBL14667945 | 0.76 | POLA1 (1.00) | CYP2C19POLA1LMNAHTTRECQL | |
| Aphidicolin SCHEMBL8763668 | 0.76 | POLA1 (1.00) | CYP2C19POLA1LMNAHTTRECQL | |
| Aphidicolin SCHEMBL16610406 | 0.76 | POLA1 (1.00) | CYP2C19POLA1LMNAHTTRECQL | |
| Aphidicolin SCHEMBL183956 | 0.76 | POLA1 (1.00) | CYP2C19POLA1LMNAHTTRECQL | |
| Aphidicolin SCHEMBL20770430 | 0.71 | POLA1 (0.74) | CYP2C19POLA1LMNAHTTRECQL | |
| Aphidicolin SCHEMBL20771139 | 0.68 | POLA1 (0.71) | CYP2C19POLA1LMNAHTTRECQL | |
| Aphidicolin SCHEMBL2332951 | 0.65 | POLA1 (0.59) | CYP2C19POLA1LMNAHTTRECQL | |
| Aphidicolin SCHEMBL20771749 | 0.65 | LMNA (0.61) | CYP2C19POLA1LMNAHTTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9355 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| EP-3791889-B1 | C-MET RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-21 | — | — | EP | claimed |
| WO-2023165603-A1 | DNA-PK INHIBITOR AND COMBINATION USE THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2023-09-07 | — | — | WO | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| CN-109010931-B | Interventional medical device and application of aphidicolin | 上海微创医疗器械（集团）有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-11207289-B2 | Use of benzofuran lignans to induce IL-25 expression and suppress mammary tumor metastasis | ACADEMIA SINICA (TW) | 2021-12-28 | — | — | US | claimed |
| EP-3791889-A1 | C-MET RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | Cedars-Sinai Medical Center (US) | 2021-03-17 | — | — | EP | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1549247-A1 | DRUG RELEASE FROM ANTITHROMBOGENIC MULTI-LAYER COATED STENT | Mediplex Corporation (KR) | 2005-07-06 | — | — | EP | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| WO-2004028406-A1 | DRUG RELEASE FROM ANTITHROMBOGENIC MULTI-LAYER COATED STENT | MEDIPLEX CORPORATION (KR) | 2004-04-08 | — | — | WO | claimed |
| US-6702850-B1 | Multi-coated drug-eluting stent for antithrombosis and antirestenosis | MEDIPLEX CORPORATION KOREA (KR) | 2004-03-09 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| CN-1135332-A | Local therapy for skin virus infection | TCW PHARMACEUTICAL CO LTD (US) | 1996-11-13 | — | — | CN | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |